Resultats de la cerca - Paul J. Ross

Refinar resultats
  1. 1
    Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma

    Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma per Dimitra Repana, Paul J. Ross

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

    Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions per Chara Stavraka, Hannah Rush, Paul J. Ross

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer

    Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer per Francesca Negri, A. Wotherspoon, David Cunningham, A. Norman, Geoff Chong, Paul J. Ross

    Publicat 2005
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data

    Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Indiv... per Ian Chau, Andy Norman, David Cunningham, Justin S. Waters, Jacqui Oates, Paul J. Ross

    Publicat 2004
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

    Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? per Paul J. Ross, S. Ashley, A. Norton, K. Priest, Justin S. Waters, Tim Eisen, Ian E. Smith, Mary O’Brien

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    The impact of low-grade toxicity in older people with cancer undergoing chemotherapy

    The impact of low-grade toxicity in older people with cancer undergoing chemotherapy per Tania Kalsi, G. Babic-Illman, Paul Fields, Simon Hughes, N. Maisey, Paul J. Ross, Yanzhong Wang, Danielle Harari

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people

    The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people per Tania Kalsi, G. Babic-Illman, Paul J. Ross, N. Maisey, Simon Hughes, Paul Fields, Finbarr C. Martin, Yanzhong Wang, Danielle Harari

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

    Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer per Sheela Rao, David Cunningham, Robert E. Hawkins, Mark Hill, David B. Smith, F. Daniel, Paul J. Ross, J. Oates, A. Norman

    Publicat 2005
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort

    The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort per Paul Nderitu, Cecilia Bosco, Hans Garmo, Lars Holmberg, Håkan Malmström, Niklas Hammar, Göran Walldius, Ingmar Jungner, Paul J. Ross, Mieke Van Hemelrijck

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

    Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity per A Loganayagam, Mónica Hernández, Adele Corrigan, Lynette D. Fairbanks, Cathryn M. Lewis, Peter Harper, N. Maisey, Paul J. Ross, Jeremy Sanderson, Anthony M. Marinaki

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

    A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer per Paul J. Ross, A. Norman, David Cunningham, Andrew Webb, Timothy Iveson, Anwar R. Padhani, J Prendiville, Maggie Watson, Alison Massey, Răzvan Popescu, J. Oates

    Publicat 1997
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer

    Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer per Ian Chau, Gina Brown, David Cunningham, Diana Tait, Andrew Wotherspoon, A. Norman, Niall C. Tebbutt, Mark Hill, Paul J. Ross, Alison Massey, J. Oates

    Publicat 2006
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer

    The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer per Ian Chau, Mark Allen, David Cunningham, A. Norman, Gina Brown, Hugo Ford, Niall C. Tebbutt, Diana Tait, Mark Hill, Paul J. Ross, Jacqui Oates

    Publicat 2004
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

    Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study per Thierry André, Jose M. Reyes-Vidal, Lætitia Fartoux, Paul J. Ross, Myles Leslie, Olivier Rosmorduc, Michael Clemens, Christophe Louvet, N. Perez, Faisal Mehmud, Werner Scheithauer

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

    Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials per Gunnar Folprecht, David Cunningham, Paul J. Ross, Bengt Glimelius, Francesco Di Costanzo, J. Wils, Werner Scheithauer, P Rougier, Enrique Aranda, Hartmut Hecker, C.-H. Köhne

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials

    Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials per Ángela Lamarca, Paul J. Ross, Harpreet Wasan, Richard Hubner, Mairéad G. McNamara, Andre Lopes, Prakash Manoharan, Daniel G. Palmer, John Bridgewater, Juan W. Valle

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC)

    Search: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients with Hepatocellular Carcinoma (HCC) per Andrew X. Zhu, Olivier Rosmorduc, J Evans, Paul J. Ross, Antonino Santoro, F.J. Carrilho, M. Leberre, Maj‐Britt Jensen, Gudrun Meinhardt, Yu-chen Kang

    Publicat 2012
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

    A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer per Ian Chau, A. Norman, David Cunningham, Diana Tait, Paul J. Ross, Timothy Iveson, Mark Hill, Tamas Hickish, F. Lofts, Duncan I. Jodrell, Andrew Webb, J. Oates

    Publicat 2005
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

    Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer per Andrea Saini, A. Norman, David Cunningham, Ian Chau, Mark Hill, Diana Tait, Tamas Hickish, Timothy Iveson, F. Lofts, Duncan I. Jodrell, Paul J. Ross, J. Oates

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

    SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma per Andrew X. Zhu, Olivier Rosmorduc, T.R. Jeffry Evans, Paul J. Ross, Armando Santoro, Flair José Carrilho, Jordi Bruix, Shukui Qin, Paul J. Thuluvath, Josep M. Llovet, Marie-Aude LeBerre, Markus Jensen, Gerold Meinhardt, Yoon‐Koo Kang

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: